Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

Background and Purpose—This study was designed to evaluate the effectiveness and
safety of rivaroxaban in real-world practice compared with effectiveness and safety of …

Studies that generate real-world evidence on the effects of medical products through
analysis of digital data collected in clinical practice provide key insights for regulators …

Background Nonvitamin K antagonist oral anticoagulants (NOACs) are alternatives to
warfarin in patients with nonvalvular atrial fibrillation. Randomized trials compared NOACs …

Randomised controlled trials (RCTs) provide the reference standard for comparing the
efficacy of one therapy or intervention with another. However, RCTs have restrictive …

Ibrutinib is a transformative therapy for high-risk and relapsed refractory chronic lymphocytic
leukemia (CLL) patients. In clinical trials in relatively healthy younger patients, ibrutinib has …

Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …

Appropriate chemoprophylaxis choice following arthroplasty requires accurate patient risk
assessment. We compared the results of our prospective department protocol to the Caprini …

Objective: To compare the risk of stroke/systemic embolism (S/SE) and major bleeding (MB)
of elderly (≥ 65 years of age) nonvalvular atrial fibrillation (NVAF) patients initiating …

Direct-acting oral anticoagulants (DOACs) have provided benefit in patients requiring
anticoagulation for certain diseases by decreasing the burden of subcutaneous injections …